Intestinal fibrosis is associated with lack of response to Infliximab therapy in Crohn's disease.

Overt fibrostenotic disease is a relative contraindication for anti-TNF therapy in Crohn's disease. We hypothesized that subclinical fibrosis may also contribute to an incomplete response to anti-TNF therapy before the onset of symptomatic stenosis.In a previous trial, patients with ileocecal C...

Full description

Bibliographic Details
Main Authors:	Jessica R de Bruyn, Marte A Becker, Jessica Steenkamer, Manon E Wildenberg, Sybren L Meijer, Christianne J Buskens, Willem A Bemelman, Mark Löwenberg, Cyriel Y Ponsioen, Gijs R van den Brink, Geert R D'Haens
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2018-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC5783363?pdf=render

Internet

http://europepmc.org/articles/PMC5783363?pdf=render

Intestinal fibrosis is associated with lack of response to Infliximab therapy in Crohn's disease.

Internet

Similar Items